Unlike traditional single-pathway or dual-pathway incretin compounds, this molecule is structurally designed to activate GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously
This novel approach addresses a critical gap for patients seeking alternatives to medications like semaglutide, particularly those experiencing gastrointestinal side effects
Hers aims to change that with a monthly membership model designed to make medically-guided weight loss easier to start and manage over time
If youre looking for a more tailored approach to weight losswith medical guidance and ongoing support this limited-time discount could be worth considering
How Long Will I Need to Be on GLP-1 Therapy
However, despite their effectiveness, weight loss responses to single-agent GLP-1RAs may plateau over time, reflecting adaptive physiological mechanisms that counteract sustained energy deficit